VC
Vivo Capital Portfolio holdings
AUM
$977M
This Quarter Return
-0.55%
1 Year Return
+209.68%
3 Year Return
+1,480.07%
5 Year Return
+2,591.98%
10 Year Return
–
AUM
$1.73B
AUM Growth
+$1.73B
(+24%)
Cap. Flow
+$415M
Cap. Flow
% of AUM
23.97%
Top 10 Holdings %
Top 10 Hldgs %
59.34%
Holding
67
New
13
Increased
7
Reduced
17
Closed
3
Top Buys
| 1 |
ALX Oncology
ALXO
|
$159M |
| 2 |
Harmony Biosciences
HRMY
|
$154M |
| 3 |
Novavax
NVAX
|
$17.8M |
| 4 |
Nkarta
NKTX
|
$15.4M |
| 5 |
Cytokinetics
CYTK
|
$15.2M |
Top Sells
| 1 |
Verastem
VSTM
|
$7.98M |
| 2 |
Legend Biotech
LEGN
|
$6.94M |
| 3 |
Arcutis Biotherapeutics
ARQT
|
$5.16M |
| 4 |
Zymeworks
ZYME
|
$4.37M |
| 5 |
Galmed Pharmaceuticals
GLMD
|
$4.11M |
Sector Composition
| 1 | Healthcare | 91.47% |
| 2 | Financials | 6.31% |
| 3 | Materials | 2.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma
ASND
$11.8B
| $277M | 16.03% | 1,797,745 | – | – |
|
|
2
ALX Oncology
ALXO
$62.7M
| $159M | 9.2% | +4,220,048 | New | +$159M |
|
|
3
Harmony Biosciences
HRMY
$2.12B
| $154M | 8.88% | +4,534,341 | New | +$154M |
|
|
NFH
4
DELISTED
New Frontier Health Corporation Ordinary Shares
NFH
| $109M | 6.31% | 14,300,000 | – | – |
|
|
5
Legend Biotech
LEGN
$6.41B
| $103M | 5.94% | 3,330,269 -224,738 | -6% | -$6.94M |
|
|
GTH
6
DELISTED
Genetron Holdings Limited ADS
GTH
| $75.7M | 4.37% | 6,339,860 | – | – |
|
|
AMRS
7
DELISTED
Amyris Inc.
AMRS
| $38.4M | 2.22% | 13,158,914 +2,977,442 | +29% | +$8.69M |
|
|
SVA
8
DELISTED
Sinovac Biotech, Ltd
SVA
| $38.2M | 2.21% | 5,900,000 | – | – |
|
9
Immunovant
IMVT
$2.56B
| $36.7M | 2.12% | 1,042,460 +242,460 | +30% | +$8.53M |
|
10
Crinetics Pharmaceuticals
CRNX
$2.92B
| $35.5M | 2.05% | 2,263,770 -52,858 | -2% | -$828K |
|
|
ISEE
11
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $33.7M | 1.94% | 5,966,527 | – | – |
|
|
12
Arcutis Biotherapeutics
ARQT
$1.86B
| $32.6M | 1.89% | 1,113,265 -176,095 | -14% | -$5.16M |
|
13
Kura Oncology
KURA
$686M
| $32.2M | 1.86% | 1,050,000 | – | – |
|
|
14
Zymeworks
ZYME
$1.12B
| $29.8M | 1.72% | 640,411 -93,750 | -13% | -$4.37M |
|
15
Passage Bio
PASG
$22.7M
| $28.7M | 1.66% | 2,191,453 -38,134 | -2% | -$500K |
|
16
Celldex Therapeutics
CLDX
$1.47B
| $25.5M | 1.48% | 1,722,500 +122,500 | +8% | +$1.82M |
|
17
Arrowhead Research
ARWR
$3.05B
| $24.8M | 1.43% | 576,505 | – | – |
|
|
SAGE
18
DELISTED
Sage Therapeutics
SAGE
| $21.6M | 1.25% | 353,511 +10,332 | +3% | +$632K |
|
|
MYOK
19
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $21.6M | 1.25% | 158,310 | – | – |
|
|
KDMN
20
DELISTED
Kadmon Holdings, Inc.
KDMN
| $20.7M | 1.2% | 5,291,336 -56,432 | -1% | -$221K |
|
|
SRRA
21
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $20.5M | 1.18% | 1,917,074 | – | – |
|
22
Rocket Pharmaceuticals
RCKT
$354M
| $19.7M | 1.14% | 860,648 | – | – |
|
|
VRNA
23
Verona Pharma
VRNA
$9.16B
| $19M | 1.1% | 3,048,507 +1,555,556 | +104% | +$9.71M |
|
24
KalVista Pharmaceuticals
KALV
$678M
| $18.6M | 1.07% | 1,476,796 | – | – |
|
|
25
Novavax
NVAX
$1.21B
| $17.8M | 1.03% | +164,199 | New | +$17.8M |
|